Menu Search
Equities

Mira Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
K6S:BER

Mira Pharmaceuticals Inc

Actions
  • Price (EUR)1.55
  • Today's Change-0.20 / -11.43%
  • Shares traded--
  • 1 Year change+113.79%
  • Beta--
Data delayed at least 15 minutes, as of Jul 18 2025 20:40 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in pain management, depression, PTSD and cognitive function. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial. It is for patients suffering from neuropathic pain, treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD). MIRA-55 is a preclinical-stage investigational drug designed to support cognitive function and enhance memory. It is for the treatment of patients experiencing cognitive decline, including those with early neurodegenerative conditions.

  • Revenue in USD (TTM)0.00
  • Net income in USD-7.92m
  • Incorporated2020
  • Employees--
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		MIRA:NAQ since
announced		Transaction
value
SKNY Pharmaceuticals IncAnnounced24 Mar 202524 Mar 2025Announced40.63%5.00m
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.